Literature DB >> 11897981

The cellular biology of eosinophil eicosanoid formation and function.

Christianne Bandeira-Melo1, Patricia T Bozza, Peter F Weller.   

Abstract

Eosinophils are capable of generating eicosanoid derivatives of arachidonic acid by means of cyclooxygenase and the 5- and 15-lipoxygenase (LO) pathways. Moreover, eosinophils, because of their expression of leukotriene (LT) C(4) synthase, are a major source of 5-LO-derived cysteinyl LTs, which are potent paracrine mediators of bronchial obstruction and inflammation pertinent to asthma. The regulation of eicosanoid formation within eosinophils involves activation of key enzymes at specific intracellular sites. Calcium ionophore-elicited translocation of 5-LO to the membranes of the nuclear envelope is associated with LTC(4) formation. In addition, lipid bodies, the formation of which is initiated by specific receptor-mediated signaling pathways, are sites of cyclooxygenase- and LO-pathway eicosanoid formation. Newly formed LTC(4) can be immunolocalized at perinuclear membranes in ionophore-activated eosinophils and at lipid bodies in CCR3 agonist (eg, eotaxin) chemokine-stimulated eosinophils. The local generation of eicosanoids at distinct sites within eosinophils may be important for the roles of these eicosanoids, both as paracrine mediators pertinent to inflammation and as intracrine signal-transducing mediators that help regulate cellular responses of eosinophils.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11897981     DOI: 10.1067/mai.2002.121529

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  26 in total

Review 1.  Paradigm shift in the pharmacological management of periodontal diseases.

Authors:  Hatice Hasturk; Alpdogan Kantarci; Thomas E Van Dyke
Journal:  Front Oral Biol       Date:  2011-11-11

2.  Co-operative signalling through DP(1) and DP(2) prostanoid receptors is required to enhance leukotriene C(4) synthesis induced by prostaglandin D(2) in eosinophils.

Authors:  F P Mesquita-Santos; I Bakker-Abreu; T Luna-Gomes; P T Bozza; B L Diaz; C Bandeira-Melo
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

Review 3.  Identifying intracellular sites of eicosanoid lipid mediator synthesis with EicosaCell assays.

Authors:  Christianne Bandeira-Melo; Peter F Weller; Patricia T Bozza
Journal:  Methods Mol Biol       Date:  2011

4.  EicosaCell: An Imaging-Based Assay to Identify Spatiotemporal Eicosanoid Synthesis.

Authors:  Christianne Bandeira-Melo; Ligia Almeida Paiva; Natália R T Amorim; Peter F Weller; Patricia T Bozza
Journal:  Methods Mol Biol       Date:  2017

Review 5.  The expanding role(s) of eosinophils in health and disease.

Authors:  Elizabeth A Jacobsen; Richard A Helmers; James J Lee; Nancy A Lee
Journal:  Blood       Date:  2012-08-30       Impact factor: 22.113

6.  LEUKOCYTE LIPID BODIES - STRUCTURE AND FUNCTION AS "EICOSASOMES".

Authors:  Peter F Weller
Journal:  Trans Am Clin Climatol Assoc       Date:  2016

7.  Eosinophils as a novel cell source of prostaglandin D2: autocrine role in allergic inflammation.

Authors:  Tatiana Luna-Gomes; Kelly G Magalhães; Fabio P Mesquita-Santos; Ilka Bakker-Abreu; Rafaela F Samico; Raphael Molinaro; Andrea S Calheiros; Bruno L Diaz; Patrícia T Bozza; Peter F Weller; Christianne Bandeira-Melo
Journal:  J Immunol       Date:  2011-11-18       Impact factor: 5.422

Review 8.  Key mediators in the immunopathogenesis of allergic asthma.

Authors:  Sannette Hall; Devendra K Agrawal
Journal:  Int Immunopharmacol       Date:  2014-06-13       Impact factor: 4.932

Review 9.  Mast cells and eosinophils: the two key effector cells in allergic inflammation.

Authors:  Yael Minai-Fleminger; Francesca Levi-Schaffer
Journal:  Inflamm Res       Date:  2009-05-08       Impact factor: 4.575

Review 10.  Challenges in the synthesis of a unique mono-carboxylic acid antibiotic, (+)-zincophorin.

Authors:  Zhenlei Song; Andrew G Lohse; Richard P Hsung
Journal:  Nat Prod Rep       Date:  2009-04       Impact factor: 13.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.